Welcome to our dedicated page for Kiromic Biopharma news (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on Kiromic Biopharma stock.
Kiromic BioPharma, Inc. (OTCQB: KRBP) is a clinical-stage biotherapeutics company focused on immuno-oncology, and the KRBP news page highlights company announcements, clinical updates and regulatory milestones. Kiromic is developing a multi-indication allogeneic cell therapy platform that uses gamma delta T-cells to target solid tumors, with its lead investigational product Deltacel™ (KB-GDT-01) in a Phase 1 trial for stage 4 non-small cell lung cancer (NSCLC) that has failed standard therapies.
News items for KRBP frequently cover progress in the Deltacel-01 clinical trial, including safety observations, tumor volume changes, partial responses, stable disease assessments and progression-free survival data in individual patients. The company also reports on decisions from the Deltacel-01 Safety Monitoring Committee, transitions from initial cohorts into expansion phases, and the activation of additional clinical trial sites such as the Beverly Hills Cancer Center, Texas Oncology in Tyler, Virginia Oncology Associates and the University of Arizona Cancer Center.
Regulatory and corporate developments appear in this feed as well, including Kiromic’s announcement that the U.S. Food and Drug Administration granted Fast Track designation to Deltacel in combination with low-dose radiation for certain metastatic NSCLC patients, and the company’s disclosure of a settlement agreement with the U.S. Securities and Exchange Commission related to prior non-disclosure of FDA clinical holds.
Investors and observers can use the KRBP news page to follow Kiromic’s ongoing clinical results, site expansions, regulatory designations and corporate updates related to its gamma delta T-cell platform and DIAMOND® AI 2.0 target discovery engine. Regular review of this page can help track how the Deltacel-01 program and Kiromic’s broader immuno-oncology strategy evolve over time.
Kiromic BioPharma (Nasdaq: KRBP) has completed and certified its GMP facility in Houston, Texas, meeting all FDA guidelines. This facility will support the company's upcoming first-in-human CAR-T trial targeting ovarian cancer. Key targets include chPD1 Gamma-Delta and anti-ISOMSLN. The Gamma-Delta-T cell GMP manufacturing test batch optimization is on schedule.
CEO Dr. Maurizio Chiriva-Internati emphasized that in-house manufacturing enhances trial efficiency. GDT cells, derived from healthy donors, promise to be more effective in targeting tumors compared to traditional T cells.
Kiromic Biopharma (Nasdaq: KRBP) has announced the filing of crucial European patents for its chimeric PD-1 (chPD1) target, focusing on immuno-oncology. The chPD1 receptor interacts with PD-1 ligands on various cancer cells, including those from ovarian and breast cancers, activating T-cells to destroy tumors. Preclinical data shows a 100% long-term progression-free survival rate in nine in vivo models. Kiromic's chPD1 will enhance their CAR-T therapy platform, led by Prof. Amorette Barber from Longwood University, aiming for significant advancements in cell therapies.
Kiromic BioPharma (NASDAQ: KRBP), a pioneer in immuno-oncology, has submitted two IND applications to the FDA for Phase 1 trials of its allogenic CAR-T therapy targeting epithelial ovarian carcinoma and malignant pleural mesothelioma. The therapy, leveraging gamma-delta T cells, aims to reduce costs, enhance efficacy, and improve safety. The trials will enroll approximately 12 patients over four months, with initial dosing expected in Q1 2021. This represents a significant advancement in CAR-T treatment options for solid tumors, addressing a critical need in the oncology landscape.
Kiromic BioPharma (NASDAQ: KRBP), a pre-clinical biotechnology company, reported its Q3 2020 financial results, highlighting milestones in drug development focused on immune-oncology. As of September 30, cash was $469,300, down from $1,929,100 at year-end 2019, largely due to operating outflows. R&D expenses surged to $1,225,700 from $272,100, reflecting increased headcount and facility costs. The net loss widened to $2,415,700 compared to $886,900 a year prior. Kiromic aims to file two INDs for ovarian cancer in Q4 2020, bolstered by a successful $15 million IPO on October 20, enhancing its balance sheet.
Kiromic BioPharma has announced the successful closing of its initial public offering, selling 1,250,000 shares at $12.00 each, generating gross proceeds of $15 million. The offering includes a 45-day option for underwriters to purchase an additional 187,500 shares. Trading on Nasdaq under the symbol KRBP began on October 16, 2020. The offering was managed by ThinkEquity, with Paulson Investment Company as co-manager. This funding aims to support Kiromic's focus on immuno-oncology products using AI-driven gene-editing technology.
Kiromic BioPharma has announced the pricing of its initial public offering (IPO), offering 1,250,000 shares of common stock at $12.00 per share, aiming for $15 million in gross proceeds. The IPO is set to trade on the Nasdaq under the ticker KRBP from October 16, 2020, with the closing expected by October 20, 2020. An option for underwriters to purchase up to 187,500 additional shares is included. ThinkEquity is the sole book-running manager for this offering.